

20190716.13

PLik Edycja Widok Historia Zakładki Narzędzia Pomoc

Komunikat dotyczący: Polska przegrywa Komunikat Mini: Overview of the C „Questions and A Questions and an Pobierane pliki Overview of the X

Wszystkie - Dysk Google file:///C:/Users/Go%C... Pozostałe zakładki

An official website of the European Union How do you know? ▾

16 September 2020
State of the Union [Discover more](#)

 European Commission  EN

Home About us Our priorities News and media Topics Resources Europe and you

Home > [Strategy and policy](#) > [Coronavirus response](#) > Overview of the Commission's response

Overview of the Commission's response

 Find out how the von der Leyen Commission helped the EU overcome COVID-19, supporting vaccines rollout and protecting livelihoods, and prepared for health threats.

Page contents

About

Securing safe and effective vaccines for Europe and the world

Economic measures

About

The European Commission is working on all fronts to contain the spread of the coronavirus, support national health systems and counter the socio-economic impact of the pandemic by taking unprecedented measures at both national and EU level.

European Commission's coronavirus response team

[Share feedback](#)

https://commission.europa.eu/strategy-and-policy/coronavirus-response/overview-commissions-response_en#accept

PL 12:30 2020-09-17

Page contents

About

Securing safe and effective vaccines for Europe and the world

Economic measures

Public health

Borders and mobility

Fighting disinformation

Documents

Securing doses of vaccines and supporting vaccination in EU countries

The Commission has built a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 8 promising vaccine developers, securing a portfolio of up to 4.2 billion doses:



- [BioNTech-Pfizer](#) for up to 2.4 billion doses
- [AstraZeneca](#) for up to 400 million doses
- [Sanofi-GSK](#) for up to 300 million doses
- [Johnson and Johnson](#) for up to 400 million doses
- [Moderna](#) for up to 460 million doses
- [Novavax](#) for up to 200 million doses
- [Valneva](#) for up to 1.2 million doses
- [HIPRA Human Health](#) for up to 250 million doses

Share feedback

Since December 2020, the Commission has granted six conditional marketing authorisations for COVID-19 vaccine: to [BioNTech and Pfizer](#) (21 December 2020), [Moderna](#) (6 January 2021), [AstraZeneca](#) (29 January 2021), [Johnson & Johnson](#) (11 March 2021), [Novavax](#) (20 December 2021) and [Valneva](#) (24 June 2022).

Deliveries of vaccine doses to Member States have increased steadily since December 2020. Vaccination gathered pace across the European Union, and by mid-2022, 86% of adult EU population were fully vaccinated.